

BRIEF DESCRIPTION OF PUBLISHED TRIALS

AB-DENTALAC GUM (*Lactobacillus brevis* CECT 7480, *Lactobacillus plantarum* CECT 7481 and *Pediococcus acidilactici* CECT 8633) is a patented probiotic for dental health, prevents the formation of plaque halitosis and decay. It works as adjuvant treatment after tooth extraction.

- Bosch et al. 2012 (Isolation and characterization of probiotic strains for improving oral health) in vitro study was carried out to select the best strains based on its specific biofunctionalities for improving oral health (their ability to survive to oral conditions, capacity of stablishing biofilms and inhibiting plaque formation by pathogens, antagonistic activity against oral pathogens).
- Montero et al. 2017 (Clinical and microbiological effect of the adjunctive use of probiotics in the treatment of gingivitis: A randomized controlled clinical trial)
 The use of probiotic tablets containing AB-Dentalac GUM strains showed a significant reduction in the number of sites with severe inflammation, furthermore the adjunctive use of the probiotic promoted a significant microbiological impact reducing *Tannerella forsythia* (associated to bleeding spots and gingivitis).
- Pons et al. 2018 (Oral probiotic reduces pain after third molar extraction procedure) - the administration of AB-Dentalac GUM after third molar extraction helps achieve a larger reduction in local pain and eating difficulty, improving quality of life of patients.
- Nart et al. 2020 (Oral colonization by Lactobacillus brevis KABPTM-052 and Lactobacillus plantarum KABPTM-051: A Randomized, Double-Blinded, Placebo-Controlled Trial (Pilot Study) clinical trial demonstrates that the supplementation with probiotic strain Lactobacillus brevis KABPTM-052 and Lactobacillus plantarum KABPTM-051 significantly increases the concentration of L. plantarum and L. brevis species in the oral cavity.